Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Dec 21, 2017 7:57pm

143 Views

Post# 27210983

RE:Upgraded morningstar fair valuation $0.19

StrikingMoose wrote:

Hopefully when they start the metabolic studies in January they will give an update on enrolment. With the metabolic study and good results in their pocket they can dress it up nice and fly around NA doing presentations with 346 on a nice shiny platter and get us that big payday finally :D

Didn't think they were starting metabolic in January, I thought that was starting a little later. Must of missed that. Was that in MD&A? a NR?

Bullboard Posts

Debt-free cannabis company set for next stage of growth